Patents Assigned to Charlotte-Mecklenburg Hospital Authority
  • Publication number: 20050196868
    Abstract: A method for diagnosing and monitoring pulmonary hypertension using free hemoglobin, as well as surrogates for free hemoglobin, as markers for pulmonary hypertension. Bodily fluids, such as blood, serum, plasma, urine and/or breathe condensate may be collected and analyzed to determine the concentration of free hemoglobin or surrogates of free hemoglobin. The concentration indicates the presence or absence of pulmonary hypertension.
    Type: Application
    Filed: March 3, 2005
    Publication date: September 8, 2005
    Applicant: The Charlotte-Mecklenburg Hospital Authority
    Inventors: Jeffrey Kline, John Zagorski
  • Patent number: 6936048
    Abstract: The invention is a transvaginal ultrasound probe having an attached echogenic needle that is useful in the treatment of uterine fibroids. The echogenic needle has an echogenic surface near its tip that allows the physician to visualize its location using ultrasound imaging. In one embodiment, the needle has an active electrode at its distal end. The active electrode supplies radio frequency energy to a fibroids causing necrosis of the targeted fibroid or by destroying the fibroid's vascular supply. The radio frequency needle preferably has a safety device that shuts-off energy if the needle punctures the uterine wall. In a second embodiment, the needle has a cryogen supply tube and cryogen supply. This embodiment destroys fibroid tissue by freezing it or its vascular supply when the tissue comes in contact with the needle's frozen distal end. The invention further includes the method of using the ultrasound probe with the attached needle.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: August 30, 2005
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Bradley Shawn Hurst
  • Patent number: 6796949
    Abstract: This invention provides a sock containing a coating material such as a coloring agent or dye, applied to at least a portion of the interior surface of the sock for sensing pressure points on a patient's foot to which the sock is fitted. The sock is placed on the patient's foot to cover preferably the entire foot, but at least the bottom portion thereof. The sock is removed after being worn for a period of time, and in those areas of the foot susceptible to pressure points, the coating material transfers from the interior of the sock and adheres to the foot in those points. The present invention is particularly applicable to a person having diabetic neuropathic feet wherein portions of the foot may be insensitive to pressure and therefore must be protected against pressure sores.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: September 28, 2004
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: James M. Horton
  • Patent number: 6793639
    Abstract: A pelvic splint for immobilizing and maintaining the annular integrity of the pelvis in the event of a pelvic ring fracture. The pelvic splint extends from about 5-10 cm above the iliac crest down to about the middle third of the thighs and substantially encircles the pelvis of the victim. The splint is then secured about the pelvis of the victim with two or more adjustable straps. The splint comprises a flexible casing having at least one pliable padding layer disposed therein and a plurality of flexible members individually disposed in pockets spaced apart about the casing. Once tightly secured around the pelvis by the adjustable straps, the splint conforms to the contours of the victim's pelvic area and stabilizes the pelvis by preventing lateral movement and constraining the pelvis in such a manner to preserve the annular integrity thereof. An associated method of stabilizing a pelvis is also disclosed.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: September 21, 2004
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventors: Michael A. Gibbs, Michael Bosse, John Marx, Steven Colucciello, David Jacobs, Barbara Ozmar
  • Publication number: 20040171678
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: February 25, 2004
    Publication date: September 2, 2004
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Publication number: 20040162500
    Abstract: A diagnosis method for respiratory disease based on the separation of the expired airway phase in an exhaled breath from the alveolar phase, and a device to accomplish the method. The device includes a cartridge assembly and a disposable condensing chamber carried in a substantially enclosed housing. The cartridge assembly includes a disposable cartridge and a reusable control system that monitors a characteristic of gas passing through the cartridge to determine when to divert the exhaled breath to an exhaust outlet and when to divert the exhaled breath to the condensing chamber. The characteristic is selected as being representative of the transition from the expired airway phase to the alveolar phase. Also included are a refrigeration system, an auxiliary monitoring system for determining when a sufficient volume of gas has been produced, and a built-in analyzer.
    Type: Application
    Filed: February 13, 2004
    Publication date: August 19, 2004
    Applicant: The Charlotte-Mecklenburg Hospital Authority
    Inventor: Jeffrey A. Kline
  • Publication number: 20040143252
    Abstract: The invention is a transvaginal ultrasound probe having an attached echogenic needle that is useful in the treatment of uterine fibroids. The echogenic needle has an echogenic surface near its tip that allows the physician to visualize its location using ultrasound imaging. In one embodiment, the needle has an active electrode at its distal end. The active electrode supplies radio frequency energy to a fibroids causing necrosis of the targeted fibroid or by destroying the fibroid's vascular supply. The radio frequency needle preferably has a safety device that shuts-off energy if the needle punctures the uterine wall. In a second embodiment, the needle has a cryogen supply tube and cryogen supply. This embodiment destroys fibroid tissue by freezing it or its vascular supply when the tissue comes in contact with the needle's frozen distal end. The invention further includes the method of using the ultrasound probe with the attached needle.
    Type: Application
    Filed: January 16, 2003
    Publication date: July 22, 2004
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Bradley Shawn Hurst
  • Patent number: 6706759
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: March 16, 2004
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Publication number: 20040019102
    Abstract: There is provided a method for inhibiting ATF/CREB and cancer cell growth using disulfiram, administered in combination with heavy metals. It was found that disulfiram disrupts transcription factor DNA binding by forming mixed disulfides with thiols within the DNA-binding region, and that this process is facilitated by metal ions. Disulfiram administered to melanoma cells in combination with copper (II) or zinc(II) decreased expression of cyclin A, reduced proliferation in vitro, and inhibited growth of melanoma cells. The combination of oral zinc gluconate and disulfiram at currently approved doses for alcoholism stabilized tumor growth in two of three patients with Stage IV metastatic melanoma, with 12 and 17 month survivals, respectively, to date, and produced a >50% reduction in hepatic metastases in one individual.
    Type: Application
    Filed: May 14, 2003
    Publication date: January 29, 2004
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Publication number: 20030229064
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Application
    Filed: March 3, 2003
    Publication date: December 11, 2003
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventor: Thomas Preston Kennedy
  • Patent number: 6589987
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide strongly inhibits the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: July 8, 2003
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Publication number: 20030073942
    Abstract: A pelvic splint for immobilizing and maintaining the annular integrity of the pelvis in the event of a pelvic ring fracture. The pelvic splint extends from about 5-10 cm above the iliac crest down to about the middle third of the thighs and substantially encircles the pelvis of the victim. The splint is then secured about the pelvis of the victim with two or more adjustable straps. The splint comprises a flexible casing having at least one pliable padding layer disposed therein and a plurality of flexible members individually disposed in pockets spaced apart about the casing. Once tightly secured around the pelvis by the adjustable straps, the splint conforms to the contours of the victim's pelvic area and stabilizes the pelvis by preventing lateral movement and constraining the pelvis in such a manner to preserve the annular integrity thereof. An associated method of stabilizing a pelvis is also disclosed.
    Type: Application
    Filed: November 21, 2002
    Publication date: April 17, 2003
    Applicant: Charlotte-Mecklenburg Hospital Authority d/b/a Carolinas Medical Center
    Inventors: Michael A. Gibbs, Michael Bosse, John Marx, Steven Colucciello, David Jacobs, Barbara Ozmar
  • Patent number: 6548540
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 15, 2003
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Patent number: 6503217
    Abstract: A pelvic splint for immobilizing and maintaining the annular integrity of the pelvis in the event of a pelvic ring fracture. The pelvic splint extends from about 5-10 cm above the iliac crest down to about the middle third of the thighs and substantially encircles the pelvis of the victim. The splint is then secured about the pelvis of the victim with two or more adjustable straps. The splint comprises a flexible casing having at least one pliable padding layer disposed therein and a plurality of flexible members individually disposed in pockets spaced apart about the casing. Once tightly secured around the pelvis by the adjustable straps, the splint conforms to the contours of the victim's pelvic area and stabilizes the pelvis by preventing lateral movement and constraining the pelvis in such a manner to preserve the annular integrity thereof. An associated method of stabilizing a pelvis is also disclosed.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: January 7, 2003
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventors: Michael A. Gibbs, Michael Bosse, John Marx, Steven Colucciello, David Jacobs, Barbara Ozmar
  • Patent number: 6206930
    Abstract: The invention relates to an absorbable implantable tissue expander device that can be used in surgeries as a gradually diminishing space filler. The absorbable tissue expander has a fluid-tight or semipermeable envelope having a bio-absorbable biocompatible shell defining a chamber. The envelope is inflatable upon infusion of a fluid into the chamber and deflatable upon removal of the fluid from the chamber. The tissue expander also enables the controlled inflation and deflation of the envelope after the device is implanted in a tissue.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: March 27, 2001
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventors: Karen J. L. Burg, Craig Reed Halberstadt, Walter Dalton Holder, Jr.
  • Patent number: 6165445
    Abstract: There is provided novel pharmaceutical compositions containing tyloxapol as the active ingredient. These formulations comprise tyloxapol at concentrations above 0.125%, preferably from about 0.25% to about 5.0%. In addition, the invention encompasses pharmaceutical compositions having reduced hypertonicity which compositions comprise tyloxapol in pharmaceutically acceptable solutions without significant concentrations of hypertonic agents or other active ingredients NaHCO.sub.3, or active phospholipids, such as DPPC. The less hypertonic formulations allow one to derive all the benefits of the active ingredient tyloxapol, such as its reduced toxicity and enhanced half-life, while avoiding or reducing side effects, such as bronchospasms, associated with the various hypertonic agents or other active ingredient agents.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: December 26, 2000
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas P. Kennedy
  • Patent number: 6140285
    Abstract: A composition for cleaning petroleum contaminated surfaces includes 5 to 60 percent by weight of a dioctyl sulfosuccinate salt, 20 to 50 percent by weight of a carrier composition and 10 to 75 percent by weight of a diluent. The preferred carrier composition is a mixture of polyethylene glycol and glycerol. The preferred diluent is water. The preferred concentration of sodium dioctyl sulfosuccinate is about 7% by weight. The preferred dioctyl sulfosuccinate salt is sodium dioctyl sulfosuccinate. A method of cleaning petroleum contaminated surfaces is also provided. The steps include providing a solution containing dioctyl sulfosuccinate salt, a carrier composition, and a diluent as described above and treating the petroleum contaminated surface with the solution in a manner and for a time sufficient to decontaminate the surface. The preferred method of treatment comprises contacting the solution with the petroleum contaminated surface for a time sufficient to create an emulsion and then removing the emulsion.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: October 31, 2000
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventors: David M. Banks, Michael J. Bosse, Martha H. Meyer, Ralph A. Meyer, Jr., Laura S. Phieffer, Kevin L. Smith
  • Patent number: 6080579
    Abstract: There is provided a method for growing human intervertebral cells. Disc tissue is surgically removed from a normal disc of a patient, the cells expanded by feeding with a cell stimulant such as a growth factor, or a cytokine or a bioactive agent to form monolayer primary cell cultures on a plastic mesh such as a nylon mesh. In the case of a growth factor, fetal bovine serum is preferred as it improves cell proliferation and production of appropriate extracellular matrix components. In another aspect of this invention, the monolayer primary cell cultures are seeded in alginate or agarose and fed again with the cell stimulant until three-dimensional cell cultures are formed. The cells are recovered from the alginate or agarose or from monolayer cultures. Re-implantation is carried out using bioresorbable carriers or cell suspensions.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: June 27, 2000
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventors: Edward Nathaniel Hanley, Jr., Helen Elizabeth Gruber
  • Patent number: 6024940
    Abstract: A method and medicant for the inhibition of activation of the nuclear transcription NF-.kappa.B comprising administering an effective amount of a compound of the formula: ##STR1## where R=ethylene, R'=C.sub.4 to C.sub.14 straight chain or branched alkyl, x is greater than 1, and y=8 to 18 is provided. The medicant is preferably administered by aerosolization into the mammalian respiratory system. The medicant may also be applied to the mammalian skin. Preferably the medicant includes a physiologically acceptable carrier which may be selected from buffered saline, isotonic saline, normal saline, petroleum-based ointments and U.S.P. cold cream. There is further provided a method wherein the medicant includes an anti-inflammatory steroid. In addition a method and medicant for treating cutaneous inflammatory disorders, inhibiting the secretion of the pro-inflammatory cytokines TNF, IL-1, IL-6, IL-8 and the growth factor GM-CSF is provided.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: February 15, 2000
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventors: Andrew J. Ghio, Thomas P. Kennedy
  • Patent number: 5968999
    Abstract: There is provided a polymethylmethacrylate (PMMA) bone cement composition that includes the addition of from about 10% by weight to about 30% by weight of calcium hydroxide. The bone cement is used for orthopaedic procedures, injuries, or disease states that have compromised the metabolism of local hard and soft tissues, largely due to an acidic environment. In an aqueous environment, the calcium hydroxide is slowly released from pores in the polymer matrix as calcium and hydroxyl ions to provide a method for stimulating healing by maintaining or elevating local pH in the tissues adjacent to bone cement. It has also been found that the calcium hydroxide ameliorates the toxic effects of antibiotics which are often included in the bone cement.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: October 19, 1999
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventors: Warren Kibby Ramp, Richard Dennis Peindl